MINISTRY OF CHEMICALS AND FERTILISERS

DEMAND NO. 7

Department of Pharmaceuticals

(In ₹ crores)

	Actual 2024-2025			Budget 2025-2026			Revised 2025-2026			Budget 2026-2027		
	Revenue	Capital	Total	Revenue	Capital	Total	Revenue	Capital	Total	Revenue	Capital	Total
Gross	2978.80	39.99	3018.79	5267.16	1.56	5268.72	4368.20	1.50	4369.70	5929.42	1.80	5931.22
Recoveries	*-45.45*	*...*	*-45.45*	*...*	*...*	*...*	*...*	*...*	*...*	*...*	*...*	*...*
Receipts	*...*	*...*	*...*	*...*	*...*	*...*	*...*	*...*	*...*	*...*	*...*	*...*
Net	**2933.35**	**39.99**	**2973.34**	**5267.16**	**1.56**	**5268.72**	**4368.20**	**1.50**	**4369.70**	**5929.42**	**1.80**	**5931.22**
A. The Budget allocations, net of recoveries, are given below:												
CENTRE'S EXPENDITURE												
Establishment Expenditure of the Centre												
1. Secretariat	21.12	0.83	21.95	22.05	1.10	23.15	23.26	1.15	24.41	25.07	1.40	26.47
2. National Pharmaceutical Pricing Authority (NPPA)	16.14	0.16	16.30	20.60	0.40	21.00	18.15	0.35	18.50	19.00	0.40	19.40
3. Recovery	-0.06	...	-0.06	...	...	...	...	...	...	...	...	...
Total-Establishment Expenditure of the Centre	**37.20**	**0.99**	**38.19**	**42.65**	**1.50**	**44.15**	**41.41**	**1.50**	**42.91**	**44.07**	**1.80**	**45.87**
Central Sector Schemes/Projects												
4. National Institutes of Pharmaceutical Education and Research (NIPERs)	245.03	...	245.03	200.07	...	200.07	281.07	...	281.07	215.00	...	215.00
5. Jan Aushadhi Scheme	169.93	...	169.93	353.50	...	353.50	190.00	...	190.00	200.50	...	200.50
6. Consumer Awareness Publicity and Price Monitoring	4.21	...	4.21	6.00	...	6.00	4.00	...	4.00	3.00	...	3.00
Development of Pharmaceutical Industry												
7. Development of Pharmaceutical Indsutry												
7.01 Pharmaceutical Promotion & Development Scheme(PPDS)	2.02	...	2.02	5.00	...	5.00	3.83	...	3.83	2.00	...	2.00
7.02 Assistance to Pharmaceutical Industry for Common Facilities(API-CF)/Cluster Development	33.06	...	33.06	50.00	...	50.00	31.00	...	31.00	15.84	...	15.84
7.03 Pharmaceuticals Technology Upgradation Assistance Scheme(PTUAS)	...	...	...	100.00	...	100.00	92.09	...	92.09	250.00	...	250.00
7.04 Promotion of Bulk Drug Parks	2.24	...	2.24	1460.00	...	1460.00	810.00	...	810.00	700.00	...	700.00
Total- Development of Pharmaceutical Indsutry	*37.32*	*...*	*37.32*	*1615.00*	*...*	*1615.00*	*936.92*	*...*	*936.92*	*967.84*	*...*	*967.84*
Production Linked Incentive Schemes												
8. Production Linked Incentive Schemes												
8.01 Production Linked Incentive(PLI) Scheme for Promotion of Domestic Manufacturing of Critical Key Starting Materials(KSMs)/Drug Intermediates(DIs) and Active Pharmaceutical	21.30	...	21.30	40.00	...	40.00	52.86	...	52.86	66.40	...	66.40

(In ₹ crores)

	Actual 2024-2025			Budget 2025-2026			Revised 2025-2026			Budget 2026-2027		
	Revenue	Capital	Total	Revenue	Capital	Total	Revenue	Capital	Total	Revenue	Capital	Total
Ingredients(APIs) in India												
8.02 Production Linked Incentive (PLI) Scheme for Domestic Manufacturing of Medical Devices	81.99	...	81.99	104.93	...	104.93	139.85	...	139.85	183.44	...	183.44
8.03 Production Linked Incentive Scheme for Pharmaceuticals	2330.00	...	2330.00	2300.00	...	2300.00	2300.00	...	2300.00	2250.00	...	2250.00
Total- Production Linked Incentive Schemes	*2433.29*	*...*	*2433.29*	*2444.93*	*...*	*2444.93*	*2492.71*	*...*	*2492.71*	*2499.84*	*...*	*2499.84*
9. Promotion of Research and Innovation in Pharma Med-Tech (PRIP)	48.44	...	48.44	245.00	...	245.00	245.00	...	245.00	750.00	...	750.00
10. Strengthening of Medical Device Industry												
10.01 Promotion of Medical Device Parks	0.90	...	0.90	125.00	...	125.00	120.80	...	120.80	50.00	...	50.00
10.02 Capacity Building and Skill Development for Medical Devices	0.50	...	0.50	60.00	...	60.00	20.00	...	20.00	10.00	...	10.00
10.03 Common Facilities for Medical Devices Clusters	...	...	...	60.00	...	60.00	30.00	...	30.00	20.00	...	20.00
10.04 Marginal Investment Scheme for Reducing Import Dependence	1.27	...	1.27	60.00	...	60.00	1.17	...	1.17	20.00	...	20.00
10.05 Medical Device Clinical Studies Support Scheme	0.50	...	0.50	50.00	...	50.00	0.60	...	0.60	20.00	...	20.00
10.06 Medical Device Promotion Scheme	0.15	...	0.15	5.00	...	5.00	4.52	...	4.52	4.17	...	4.17
Total- Strengthening of Medical Device Industry	*3.32*	*...*	*3.32*	*360.00*	*...*	*360.00*	*177.09*	*...*	*177.09*	*124.17*	*...*	*124.17*
11. Scheme of Programme Management	...	...	...	...	...	...	...	...	...	25.00	...	25.00
12. Bio-pharma SHAKTI	...	...	...	...	...	...	...	...	...	500.00	...	500.00
13. Chemical Parks	...	...	...	...	...	...	...	...	...	600.00	...	600.00
Total-Central Sector Schemes/Projects	**2941.54**	**...**	**2941.54**	**5224.50**	**...**	**5224.50**	**4326.79**	**...**	**4326.79**	**5885.35**	**...**	**5885.35**
Other Central Sector Expenditure												
Public Sector Undertakings												
14. Assistance to PSUs	...	39.00	39.00	0.01	0.06	0.07	...	...	...	...	...	...
Others												
15. Actual Recoveries	-45.39	...	-45.39	...	...	...	...	...	...	...	...	...
Total-Other Central Sector Expenditure	**-45.39**	**39.00**	**-6.39**	**0.01**	**0.06**	**0.07**	**...**	**...**	**...**	**...**	**...**	**...**
Grand Total	***2933.35***	***39.99***	***2973.34***	***5267.16***	***1.56***	***5268.72***	***4368.20***	***1.50***	***4369.70***	***5929.42***	***1.80***	***5931.22***
B. Developmental Heads												
Economic Services												
1. Industries	2912.29	...	2912.29	5189.69	...	5189.69	4304.87	...	4304.87	5862.80	...	5862.80
2. Secretariat-Economic Services	21.06	...	21.06	22.05	...	22.05	23.26	...	23.26	25.07	...	25.07
3. Capital Outlay on Other General Economic Services	...	0.99	0.99	...	1.50	1.50	...	1.50	1.50	...	1.80	1.80
4. Loans for Chemical and Pharmaceutical Industries	...	39.00	39.00	...	0.06	0.06	...	...	...	...	...	...
Total-Economic Services	**2933.35**	**39.99**	**2973.34**	**5211.74**	**1.56**	**5213.30**	**4328.13**	**1.50**	**4329.63**	**5887.87**	**1.80**	**5889.67**
Others												

(In ₹ crores)

	Actual 2024-2025			Budget 2025-2026			Revised 2025-2026			Budget 2026-2027		
	Revenue	Capital	Total	Revenue	Capital	Total	Revenue	Capital	Total	Revenue	Capital	Total
5. North Eastern Areas	...	...	...	55.42	...	55.42	40.07	...	40.07	41.55	...	41.55
Total-Others	**...**	**...**	**...**	**55.42**	**...**	**55.42**	**40.07**	**...**	**40.07**	**41.55**	**...**	**41.55**
Grand Total	**2933.35**	**39.99**	**2973.34**	**5267.16**	**1.56**	**5268.72**	**4368.20**	**1.50**	**4369.70**	**5929.42**	**1.80**	**5931.22**

	Budget Support	IEBR	Total	Budget Support	IEBR	Total	Budget Support	IEBR	Total	Budget Support	IEBR	Total
C. Investment in Public Enterprises												
1. Karnataka Antibiotics and Pharmaceuticals Ltd	...	404.81	404.81	...	23.65	23.65	...	487.59	487.59	...	544.75	544.75
2. Indian Drugs and Pharmaceuticals Ltd	...	...	...	0.01	...	0.01	...	...	...	...	...	...
3. Hindustan Antibiotics Ltd	...	...	...	0.01	...	0.01	...	...	...	...	...	...
4. Bengal Chemicals and Pharmaceuticals Ltd	...	21.14	21.14	0.01	...	0.01	...	21.59	21.59	...	24.40	24.40
5. Bengal Immunity Ltd	...	...	...	0.01	...	0.01	...	...	...	...	...	...
6. Rajasthan Drugs and Pharmaceuticals Ltd	...	...	...	0.01	...	0.01	...	...	...	...	...	...
7. Smith Stanistreet Pharmaceuticals Ltd	...	...	...	0.01	...	0.01	...	...	...	...	...	...
Total	**...**	**425.95**	**425.95**	**0.06**	**23.65**	**23.71**	**...**	**509.18**	**509.18**	**...**	**569.15**	**569.15**

1. **Secretariat:** The provision is for the Salary and Establishment Expenditure of Department of Pharmaceuticals.

2. **National Pharmaceutical Pricing Authority (NPPA):** The provision is for the Secretariat and Establishment Expenditure of NPPA,

4. **National Institutes of Pharmaceutical Education and Research (NIPERs):** The provision is made for 7 NIPERs i.e. Mohali, Ahmedabad, Guwahati, Hajipur, Hyderabad, Kolkata and Rae Bareli for incurring salary of employees, establishment and other expenditure.

5. **Jan Aushadhi Scheme:** The provision is under the Jan Aushadhi Scheme for effective implementation of Pradhan Mantri Bhartiya Janaushadhi Pariyojana(PMBJP).

6. **Consumer Awareness Publicity and Price Monitoring:** The provision is for Consumer Awarness, Publicity and providing support to State resource units.

7.01. **Pharmaceutical Promotion & Development Scheme(PPDS):** The provision is for promotion, development and export promotion in Pharmaceuticals sector by extending financial support for conduct of seminars, conferences, exhibitions, mounting delegation to and from India for promotion of exports as well as investments, conduction studies/ consultancies for facilitating growth, export as well as critical issues affecting Pharma Sector.

7.02. **Assistance to Pharmaceutical Industry for Common Facilities(API-CF)/Cluster Development:** The Scheme would be implemented in a Public Private Partnership (PPP) mode through one time grant-in-aid to be released in various phases for creation of identified infrastructure and common facilities to a Special Purpose Vehicles (SPVs) set up for the purpose.

7.03. **Pharmaceuticals Technology Upgradation Assistance Scheme(PTUAS):** The sub-scheme is aimed at providing interest subvention to the eligible Small and Medium Scale Pharma Units having GMP compliant manufacturing facilities both for Bulk Drugs and Pharmaceuticals formulations. The eligible units intending to upgrade their manufacturing infrastructure to attain WHO-GMP norms, have to secure loan from any Financial Institution for upgrading their infrastructure and technology.

7.04. **Promotion of Bulk Drug Parks:** To promote setting up of bulk drug parks in the country for providing easy access to world class Common Infrastructure Facilities (CIF) to bulk drug units located in the park in order to significantly bring down the manufacturing cost of bulk drugs and thereby make India self-reliant in bulk drugs by increasing the competitiveness of the domestic bulk drug industry.

8.01. **Production Linked Incentive(PLI) Scheme for Promotion of Domestic Manufacturing of Critical Key Starting Materials(KSMs)/Drug Intermediates(DIs) and Active Pharmaceutical Ingredients(APIs) in India:** The objective of the scheme is to attain self-reliance and reduce import dependence in critical KSMs/DIs/APIs. Under the scheme, financial incentives shall be given based on committed investment and sales made by selected applicant for the eligible products.

8.02. **Production Linked Incentive (PLI) Scheme for Domestic Manufacturing of Medical Devices:** The scheme proposes a financial incentive to boost domestic manufacturing and attract large investment in the Medical Device Sector.

8.03. **Production Linked Incentive Scheme for Pharmaceuticals:** The objective of the scheme is to enhance India manufacturing capabilities by increasing investment and production in the sector and contributing to product diversification to high value goods in the pharmaceutical sector.

9. **Promotion of Research and Innovation in Pharma Med-Tech (PRIP):** The objective of the scheme is to encourage industry to invest in R & D in Priority areas and to inculcate the culture of quality research and nurture the pool of scientists in the country by promoting industry-academia linkage, which will lead to sustained global competitive advantage and contribute to quality employment generation in the country

10. **Strengthening of Medical Device Industry:** Medical device is a sunrise industry in India, with double digit growth rate. Due to efforts of the government in the last decade in creating a suitable eco-system and incentivizing production of medical devices through PLI scheme, production of technology intensive medical devices such CT scan, MRI, C-arm etc. has started in India.

10.01. **Promotion of Medical Device Parks:** Creation of world class infrastructure facilities in order to make Indian medical device industry a global leader. Easy access to standard testing and infrastructure facilities through creation of world class Common Infrastructure Facilities for increased competitiveness will result in significant reduction of the cost of production of medical devices leading to better availability and affordability of medical devices in the domestic market.

10.02. **Capacity Building and Skill Development for Medical Devices:** The main objective of this component is to fill up the gap existing in the education and research in medical devices sector and to ensure quality teaching, training and nurturing excellence in Medical Technology education for generating critical mass of trained human resource to meet the requirements of rapidly innovating multidisciplinary areas of Medical Technology and create R&D ecosystem for the sector.

10.03. **Common Facilities for Medical Devices Clusters:** To strengthen existing infrastructure by providing financial assistance to medical device clusters for creating Common Infrastructure Facilities, boosting domestic manufacturing capacity and improving cluster quality. Further, to support any national or state level Government or Private institutions to establish or strengthen testing facilities for medical devices to support the arising needs of the Testing Laboratories for Medical Devices due to roll-out of licensing regime of the Medical Devices w.e.f 1.10.2022, ensuring availability of more testing facilities for evaluation of medical devices on behalf of the manufacturers, as mandated under the Medical Devices Rules, 2017.

10.04. **Marginal Investment Scheme for Reducing Import Dependence:** Medical Device Industry needs specialized inputs components in manufacturing of Medical Devices. These cannot be produced by the general industry and are often imported by medical device manufacturers. They can be incentivized through grant for manufacturing of essential/key components or upstream materials or accessories or closely related products used in manufacturing of medical devices. Presently in respect of 354 medical devices, exemption from the instructions of Department of Expenditure for Global Tender Enquiry (GTE) for tenders of value below ₹ 200 crore is available owing to lack of domestic manufacturing of these devices to meet the requirement of procurement of central government hospitals. Marginal Investment Support for manufacturing of these medical devices within the country would lead to reduction in import of these items.

10.05. **Medical Device Clinical Studies Support Scheme:** Support will be provided for conducting Clinical Investigations or Pre-Clinical animal studies for medical device or Clinical Performance Evaluation of new IVDs. This will promote manufacturing of quality products with better efficacy and safety. It will also enhance credibility of domestic manufacturers to produce high quality products, opening up opportunities for them in markets outside the country.

10.06. **Medical Device Promotion Scheme:** The scheme aims to promote Medical Device Industry by bringing industry leaders, academia and policy makers together to share their knowledge and experience for overall development of the sectors. Financial support will be provided to industry bodies/associations and educational institutions to conduct meetings/ seminars/ workshops/ events/ road-shows/expos etc. for which grant will be provided by the department. Also, support for manufacturer evaluation studies, creation of database, international study missions etc. will be provided for promotion and development of the medical device industry. Department may also directly incur expenditure on industry development activities

11. **Scheme of Programme Management:** The Scheme of Programme Management is designed as an enabling and cross-cutting scheme to strengthen the implementation, monitoring and evaluation of the schemes of the Department of Pharmaceuticals, as also facilitate sectoral expertise through hiring of consultants. The Scheme will subsume the component of engagement of individual consultants and PMAs currently funded through Scheme.

12. **Bio-pharma SHAKTI:** The scheme aims to develop India as a global Biopharma manufacturing hub and to build the ecosystem for domestic production of biologics and biosimilars.

13. **Chemical Parks:** The scheme aims to support states in establishing three dedicated Chemical Parks on a cluster based Plug-and-Play model to enhance domestic chemical production and reduce import dependency.

14. **Assistance to PSUs:** These are provisions under loan kept for the 6 Pharmaceuticals Public Sector Undertakings(PSUs).